Heart failure in women: Epidemiology, biology and treatment

Women's Health

Volumn 5, Issue 5, 2009, Pages 517-527

  Shah, Rashmee U ^a   Klein, Liviu ^a   Lloyd Jones, Donald M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Epidemiology; Heart failure; Treatment; Women

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ESTROGEN; LOSARTAN; METOPROLOL SUCCINATE; PLACEBO; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

CARDIOMYOPATHY; CARDIOVERSION; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DEFIBRILLATION; EPIDEMIOLOGICAL DATA; FEMALE; HEART ASSIST DEVICE; HEART FAILURE; HEART TRANSPLANTATION; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; MEDICAL RESEARCH; MITRAL VALVE REPAIR; MORBIDITY; MORTALITY; PATIENT CARE; PREVALENCE; RESEARCH SUBJECT; REVIEW; SEX DIFFERENCE; SURVIVAL RATE; SYSTOLE; SYSTOLIC DYSFUNCTION; TREATMENT OUTCOME; WOMEN'S HEALTH; AGED; COMORBIDITY; HEART FAILURE, DIASTOLIC; HEART FAILURE, SYSTOLIC; MALE; RISK FACTOR; UNITED STATES; VERY ELDERLY;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; COMORBIDITY; DIGOXIN; FEMALE; HEART FAILURE, DIASTOLIC; HEART FAILURE, SYSTOLIC; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; RISK FACTORS; SEX FACTORS; UNITED STATES;

EID: 69849084691     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.09.50     Document Type: Review

References (73)

1. Lloyd-Jones D, Adams R, Carnethon M et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119, E21-E181 (2009).
2. Heiat A, Gross CP, Krumholz HM: Representation of the elderly, women, and minorities in heart failure clinical trials. Arch. Intern. Med. 162, 1682-1688 (2002).
3. Levy D, Kenchaiah S, Larson MG et al.: Long-term trends in the incidence of and survival with heart failure. N. Engl. J. Med. 347, 1397-1402 (2002).
4. Roger VL, Weston SA, Redfield MM et al.: Trends in heart failure incidence and survival in a community-based population. JAMA 292, 344-350 (2004).
5. Barker WH, Mullooly JP, Getchell W: Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation 113, 799-805 (2006).
6. Senni M, Tribouilloy CM, Rodeheffer RJ et al.: Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch. Intern. Med. 159(1), 29-34 (1999).
7. Gottdiener JS, Arnold AM, Aurigemma GP et al.: Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J. Am. Coll. Card. 35, 1628-1637 (2000).
8. Koelling TM, Chen RS, Lubwama RN et al.: The expanding national burden of heart failure in the United States: the influence of heart failure in women. Am. Heart J. 147, 74-78 (2004).
9. Fang J, Mensah GA, Croft JB, Keenan NL: Heart failure-related hospitalization in the US, 1979 to 2004. J. Am. Coll. Cardiol. 52, 428-434 (2008).
10. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D: Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 88, 107-115 (1993).
11. Rathore SS, Foody JM, Wang Y et al.: Sex, quality of care, and outcomes of elderly patients hospitalized with heart failure: findings from the National Heart Failure Project. Am. Heart J. 149, 121-128 (2005).
12. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD: Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J. Am. Coll. Cardiol. 39, 60-69 (2002).
13. Masoudi FA, Havranek EP, Smith G et al.: Gender, age, and heart failure with preserved left ventricular systolic function. J. Am. Coll. Cardiol. 41, 217-223 (2003).
14. Cleland JG, Swedberg K, Follath F et al.; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology: The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur. Heart J. 24, 442-463 (2003).
15. Komajda M, Follath F, Swedberg K et al.; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology: The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur. Heart J. 24, 464-274 (2003).
16. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK: The progression from hypertension to congestive heart failure. JAMA 275, 1557-1562 (1996).
17. Frazier CG, Alexander KP, Newby LK et al.: Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials. J. Am. Coll. Cardiol. 49, 1450-1458 (2007).
18. Ezekowitz JA, Kaul P, Bakal JA, Armstrong PW, Welsh RC, McAlister FA: Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J. Am. Coll. Cardiol. 53, 13-20 (2009).
19. Ghali JK, Krause-Steinrauf HJ, Adams KF et al.: Gender differences in advanced heart failure: insights from the BEST study. J. Am. Coll. Cardiol. 42, 2128-2134 (2003).
20. Simon T, Mary-Krause M, Funck-Brentano C, Jaillon P: Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation 103, 375-380 (2001).
21. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK: Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch. Intern. Med. 161, 996-1002 (2001).
22. Bibbins-Domingo K, Lin F, Vittinghoff E et al.: Predictors of heart failure among women with coronary disease. Circulation 110, 1424-1430 (2004).
23. Kenchaiah S, Evans JC, Levy D et al.: Obesity and the risk of heart failure. N. Engl. J. Med. 347, 305-313 (2002).
24. Lloyd-Jones DM, Larson MG, Leip EP et al.: Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106, 3068-3072 (2002).
25. Bleumink GS, Knetsch AM, Sturkenboom MCJM et al.: Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur. Heart J. 25, 1614-1619 (2004).
26. Ahmed A, Aban IB, Vaccarino V et al.: A propensity-matched study of the effect of diabetes on the natural history of heart failure: variations by sex and age. Heart 93, 1584-1590 (2007).
27. Gottdiener JS, McClelland RL, Marshall R et al.: Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann. Intern. Med. 137, 631-639 (2002).
28. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D: Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J. Am. Coll. Cardiol. 33, 1948-1955 (1999).
29. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC: Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J. Am. Coll. Cardiol. 47, 76-84 (2006).
30. Smith GL, Masoudi FA, Vaccarino V, Radford MJ, Krumholz HM: Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J. Am. Coll. Cardiol. 41, 1510-1518 (2003).
31. O'Meara E, Clayton T, McEntegart MB et al.: Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Circulation 115, 3111-3120 (2007).
32. Lee DS, Gona P, Vasan RS et al.: Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 119, 3070-3077 (2009).
33. Douglas PS, Katz SE, Weinberg EO, Chen MH, Bishop SP, Lorell BH: Hypertrophic remodeling: gender differences in the early response to left ventricular pressure overload. J. Am. Coll. Cardiol. 32, 1118-1125 (1998).
34. Podesser BK, Jain M, Ngoy S, Apstein CS, Eberli FR: Unveiling gender differences in demand ischemia: a study in a rat model of genetic hypertension. Eur. J. Cardiothorac. Surg. 31, 298-304 (2007).
35. Douglas PS, Otto CM, Mickel MC, Labovitz A, Reid CL, Davis KB: Gender differences in left ventricle geometry and function in patients undergoing balloon dilatation of the aortic valve for isolated aortic stenosis. NHLBI Balloon Valvuloplasty Registry. Br. Heart J. 73, 548-554 (1995).
36. Garavaglia GE, Messerli FH, Schmieder RE, Nunez BD, Oren S: Sex differences in cardiac adaptation to essential hypertension. Eur. Heart J. 10, 1110-1114 (1989).
37. van Eickels M, Grohe C, Cleutjens JP, Janssen BJ, Wellens HJ, Doevendans PA: 17β-estradiol attenuates the development of pressure-overload hypertrophy. Circulation 104, 1419-1423 (2001).
38. Pelzer T, Jazbutyte V, Hu K et al.: The estrogen receptor-α agonist 16α-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats. Cardiovasc. Res. 67, 604-612 (2005).
39. Skavdahl M, Steenbergen C, Clark J et al.: Estrogen receptor-β mediates male-female differences in the development of pressure overload hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 288, H469-H476 (2005).
40. 2+-handling in failing human myocardium. J. Mol. Cell. Cardiol. 33, 1345-1353 (2001).
41. Vizgirda VM, Wahler GM, Sondgeroth KL, Ziolo MT, Schwertz DW: Mechanisms of sex differences in rat cardiac myocyte response to β-adrenergic stimulation. Am. J. Physiol. Heart Circ. Physiol. 282, H256-H263 (2002).
42. Paulus WJ: Bene?cial effects of nitric oxide on cardiac diastolic function: the flip side of the coin. Heart Fail. Rev. 5, 337-344 (2000).
43. Regitz-Zagrosek V: Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat. Rev. Drug Discov. 5, 425-438 (2006).
44. Xu Y, Arenas IA, Armstrong SJ, Davidge ST: Estrogen modulation of left ventricular remodeling in the aged heart. Cardiovasc. Res. 57, 388-394 (2003).
45. Anderson GL, Limacher M, Assaf AR et al.: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291, 1701-1712 (2004).
46. Rossouw JE, Anderson GL, Prentice RL et al.; Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002).
47. Grady D, Herrington D, Bittner V et al.: Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/ Progestin Replacement Study Follow-up (HERS II). JAMA 288, 49-57 (2002).
48. Lindenfeld J, Ghali JK, Krause-Steinrauf HJ et al.: Hormone replacement therapy is associated with improved survival in women with advanced heart failure. J. Am. Coll. Cardiol. 42, 1238-1245 (2003).
49. Reis SE, Holubkov R, Young JB, White BG, Cohn JN, Feldman AM: Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies. J. Am. Coll. Cardiol. 36, 529-533 (2000).
50. Bibbins-Domingo K, Lin F, Vittinghoff E et al.: Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. Am. J. Cardiol. 95, 289-291 (2005).
51. Ghali JK, Pina IL, Gottlieb SS, Deedwania PC, Wikstrand JC: Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 105, 1585-1591 (2002).
52. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353, 2001-2007 (1999).
53. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353, 9-13 (1999).
54. Packer M, Fowler MB, Roecker EB et al.: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation 106, 2194-2199 (2002).
55. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293-302 (1991).
56. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI: Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 361, 1843-1848 (2003).
57. Flather MD, Yusuf S, Kober L et al.: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355, 1575-1581 (2000).
58. McMurray JJV, Ostergren J, Swedberg K et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362, 767-771 (2003).
59. Pitt B, Poole-Wilson PA, Segal R et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 355, 1582-1587 (2000).
60. Pitt B, Segal R, Martinez FA et al.: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349, 747-752 (1997).
61. Hudson M, Rahme E, Behlouli H et al.: Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure - a population study. Eur. J. Heart Fail. 9, 602-609 (2007).
62. The Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med. 336, 525-533 (1997).
63. Rathore SS, Wang Y, Krumholz HM: Sex-based differences in the effect of digoxin for the treatment of heart failure. N. Engl. J. Med. 347, 1403-1411 (2002).
64. Ahmed A, Rich MW, Love TE et al.: Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc ana lysis of the DIG trial. Eur. Heart J. 27, 178-186 (2006).
65. Lenzen MJ, Rosengren A, Scholte op Reimer WJ et al.: Management of patients with heart failure in clinical practice: differences between men and women. Heart 94, E10 (2008).
66. Yancy CW, Fonarow GC, Albert NM et al.: Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Am. Heart J. 157, 754-762 (2009).
67. Curtis LH, Al-Khatib SM, Shea AM, Hammill BG, Hernandez AF, Schulman KA: Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. JAMA 298, 1517-1524 (2007).
68. Hernandez AF, Fonarow GC, Liang L et al.: Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA 298, 1525-1532 (2007).
69. Bardy GH, Lee KL, Mark DB et al.; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 352, 225-237 (2005).
70. Peterson PN, Daugherty SL, Wang Y et al.; National Cardiovascular Data Registry: Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy. Circulation 119, 1078-1084 (2009).
71. Lucas FL, DeLorenzo MA, Siewers AE, Wennberg DE: Temporal trends in the utilization of diagnostic testing and treatments for cardiovascular disease in the United States, 1993-2001. Circulation 113, 374-379 (2006).
72. Liu JH, Zingmond DS, McGory ML et al.: Disparities in the utilization of high-volume hospitals for complex surgery. JAMA 296, 1973-1980 (2006).
73. Hernandez AF, Grab JD, Gammie JS et al.: A decade of short-term outcomes in post cardiac surgery ventricular assist device implantation: data from the Society of Thoracic Surgeons' National Cardiac Database. Circulation 116, 606-612 (2007).